Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Investigator training: A three-day training course for clinical investigators on scientific, ethical and regulatory aspects of trials will be held Nov. 16-18 in Silver Spring, Md. (1"The Gray Sheet" May 11, 2009). The event is co-sponsored by FDA and the FDA/Duke University Clinical Trials Transformation Initiative. Participants must register at 2https://www.trialstransformation.org/course-registration by Nov. 2. Rachel Behrman, director of FDA's Office of Critical Path Programs, will run a session on FDA regulations and investigators' responsibilities in clinical trials. Cardiovascular Devices Division Director Bram Zuckerman will discuss clinical trial design issues for devices. Microbiology Devices Director Sally Hojvat will discuss diagnostic and combination product trial questions, according to a preliminary 3agenda
You may also be interested in...
Greater FDA Transparency Could Benefit Industry, Too, Trade Reps Say
Despite concerns with maintaining trade secret protections, industry has much to gain from increased openness by FDA, device industry representatives said at a June 24 meeting of FDA's new Transparency Task Force
Clinical investigation 101
Agency's Office of Critical Path Programs will launch a three-day training course for clinical investigators in November, designed to improve the quality and efficiency of trials and improve investigators' understanding of the scientific, ethical and regulatory issues involved in clinical research. Lectures and discussions will be conducted by more than 20 senior staff from FDA's device, drug and biologics centers
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”